Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat

Archives of Physiology and Biochemistry

Volumn 117, Issue 4, 2011, Pages 241-249

  Smith, G C ^a   Vickers, M H ^b   Shepherd, P R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Clozapine; GLP 1; Glucagon; Hepatic glucose production; Olanzapine; Schizophrenia; Type 2 diabetes

Indexed keywords

BENZODIAZEPINE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE;

ANIMAL; ARTICLE; BIOSYNTHESIS; BODY COMPOSITION; BODY WEIGHT; DRUG ANTAGONISM; DRUG EFFECT; FOOD PREFERENCE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; LIPID DIET; LIVER; MALE; METABOLISM; OBESITY; PSYCHOLOGICAL ASPECT; RAT; SCHIZOPHRENIA; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY COMPOSITION; BODY WEIGHT; DIET, HIGH-FAT; FOOD PREFERENCES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; OBESITY; RATS; SCHIZOPHRENIA; WEIGHT GAIN;

ANIMALIA; RATTUS;

EID: 80053012915     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2011.576681     Document Type: Article

References (53)

1. ADA. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27:596-601.
2. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M, Bergman RN. (2005). Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes, 54:862-71. (Pubitemid 40322092)
3. Ahrén B. (2007). Dipeptidyl peptidase-4 inhibitors. Diabetes Care, 30:1344-50.
4. Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, Joyal JL, Lynch CJ. (2011). Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry 16:569-581.
5. Allison DB, Montore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psych 156:1686-96. (Pubitemid 29517559)
6. Anini Y, Hansotia T, Brubaker PL. (2002). Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology 143(6):2420-6. (Pubitemid 34521588)
7. Anini Y, Brubaker PL. (2003). Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 144(7):3244-50. (Pubitemid 36819927)
8. Arjona AA, Zhang SX, Adamson B, Wurtman RJ. (2004). An animal model of antipsychotic-induced weight gain. Behav Brain Res 152:121-7. (Pubitemid 38597070)
9. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM. (2010a). Preclinical models of antipsychotic drug-induced metabolic side efects. Trends Pharmacol Sci 31(10):484-97.
10. Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, Pang CC, Barr AM. (2010b). A parametric study of the acute efects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psych 34(6):945-54.
11. Burcelin R, Cani PD, Knauf C. (2007). Glucagon-like peptide-1 and energy homeostasis. J Nutrition 137:2534-8.
12. Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, Nobrega J, Remington G. (2009). Insulin resistance and secretion in vivo: efects of diferent antipsychotics in an animal model. Schizophr Res 108(1-3):127-33.
13. Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford JC, Goudie AJ. (2007). Efects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 21(4):405-13. (Pubitemid 47077303)
14. Cooper GD, Harrold JA, Halford JC, Goudie AJ. (2008). Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 32(2):428-36. (Pubitemid 351178959)
15. Elias AN, Hofich H. (2008). Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsychotic medications. Am J Med 121:98-104. (Pubitemid 351199456)
16. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. (2004). Convergent evidence for impaired AKT1-GSK3b signaling in schizophrenia. Nature Gen 36:131-7. (Pubitemid 38174370)
17. Fell MJ, Marshall KM, Williams J, Neill JC. (2004). Efects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharm 18:149-55. (Pubitemid 38954901)
18. Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, Cheetham S, Neill JC. (2007) Te distinct efects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharm (Berl) 194:221-31. (Pubitemid 47457949)
19. Fernandez-Egea E, Bernardo M, Parellada E, Justicia A, Garcia-Rizo C, Esmatjes E, Conget I, Kirkpatrick B. (2008). Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res 103:110-13.
20. Gardner DM, Baldessarini RJ, Waraich P. (2005). Modern antipsychotic drugs: a critical overview. Can Med J Assoc 172:1703-11. (Pubitemid 40896865)
21. Girgis RR, Javitch JA, Lieberman JA. Antipsychitic drug mechanisms: links between therapeutic efects, metabolic side efects and the insulin signaling pathway. Mol Psych 13:918-29.
22. Hirose H, Maruyama H, Ito K, Kido K, Koyama K, Saruta T. (1993). Efects of alpha 2-and beta-adrenergic agonism on glucagon secretion from perfused pancreata of normal and streptozocin-induced diabetic rats. Metabolism 42(8):1072-6. (Pubitemid 23230443)
23. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. (2007). Acute efects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic efects. Neuropsychopharmacology 32:289-97. (Pubitemid 46106936)
24. Jablensky A. (2000). Epidemiology of schizophrenia: the glow bal burden of disease and disability. Euro Arch Psych Clin Neurosci 250:274-85. (Pubitemid 32002381)
25. Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL, Gibbs EM, Zawalich WS, Rollema H. (2005). Inhibitory efects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54(5):1552-8. (Pubitemid 40586689)
26. Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L. (1994). Severe hyperglycemia associated with high doses of clozapine. Am J Psych 151:1359-64.
27. Koller EA, Schneider B, Bennett K, Duditsky G. (2001). Clozapine-associated diabetes. Am J Med 111:716-23. (Pubitemid 34017524)
28. Koller EA, Doraiswamy PM. (2002). Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841-52. (Pubitemid 34743435)
29. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. (2005). Efectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Eng J Med 253:1209-23. (Pubitemid 41345943)
30. Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB. (2008). Te once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 103:94-103.
31. Mario AJ, Cesar GB, Jose VB, Rocio PI, Obdulia MG, Teresa PP, Mari RB, Benedicto CF. (2006). Attention of antipsychotic-induced weight gain with early behavioural intervention in drug-naive frst-episode psychosis patients: a randomized controlled trial. J Clin Psych 67:1253-60.
32. Meyer JM, Davis VG, McEvoy JP, Gof DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. (2008). Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 103:104-9.
33. Minet-Ringuet J, Even PC, Guesdon B, Tome D, De Beaurepaire R. (2005). Efects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behav Brain Res 163(2):204-11. (Pubitemid 41138054)
34. Minet-Ringuet J, Even PC, Goubern M, Tome D, De Beaurepaire R. (2006a). Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 46(3):254-62. (Pubitemid 43867820)
35. Minet-Ringuet J, Even PC, Lacroix M, Tome D, De Beaurepaire R. (2006b). A model for antipsychotic-induced obesity in the male rat. Psychopharmacology (Berl) 187(4):447-54. (Pubitemid 44200516)
36. Mukherjee S, Schnur DB, Reddy R. (1989). Family history of type 2 diabetes in schizophrenia patients. Lancet 1:495. (Pubitemid 19063553)
37. Newcomer JW. (2004). Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psych 65:36-46.
38. Peters CT, Choi YH, Brubaker PL, Anderson GH. (2001). A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutrient selection by rats. J Nutr 131:2164-70. (Pubitemid 32720647)
39. Pouzet B, Mow T, Kreilgaard M, Velschow S. (2003). Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharm Biochem Behav 75:133-40. (Pubitemid 36577588)
40. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. (2007). Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56:8-15.
41. Reynolds GP, Kirk SL. (2010) Metabolic side efects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ter 125(1):169-79.
42. Rigalleau V, Gatta B, Bonnaud S, Masson M, Bourgeois ML, Vergnot V, Gin H. (2000). Diabetes as a result of atypical anti-psychotic drugs-a report of three cases. Diabet Med 17:484-6. (Pubitemid 30471346)
43. Ryan MC, Collins P, Takore JH. (2003). Impaired fasting glucose tolerance in frst-episode, drug-naive patients with schizophrenia. Am J Psych 166:284-9. (Pubitemid 41110453)
44. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. (2008). Reduced blood glucose levels, increased insulin levels and improved glucose tolerance in alpha2A-adrenoceptor knockout mice. Eur J Pharmacol 578(2-3):359-64.
45. Savoy YE, Ashton MA, Miller MW, Nedza FM, Spracklin DK, Hawthorn MH, Rollema H, Matos FF, Hajos-Korcsok E. (2010). Diferential efects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation. Schizophr Bull 36(2):410-18.
46. Sengupta S, Parrilla-Escobar MA, Klink R, Ying KN, Stip E, Baptista T, Malla A, Joober R. (2008). Are metabolic indices diferent between drug-naive frst-episode psychosis patients and healthy controls? Schizophr Res 102:329-36.
47. Shin YK, Martin B, Golden E, Dotson CD, Maudsley S, Kim W, Jang HJ, Mattson MP, Drucker DJ, Egan JM, Munger SD. (2008). Modulation of taste sensitivity by GLP-1 signaling. J Neurochem 106:455-63. (Pubitemid 351840219)
48. Smith GC, Chaussade C, Vickers M, Jensen J, Shepherd PR. (2008). Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 51:2309-17.
49. Smith GC, Vickers MH, Cognard E, Shepherd PR. (2009). Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res 115:30-40.
50. Spelman LM, Walsh PI, Sharif N, Collins P, Takore JH. (2007). Impaired glucose tolerance in frst-episode drug-naive patients with schizophrenia. Diab Med 24:481-5. (Pubitemid 46669314)
51. Tandon R, Keshavan MS, Nasrallah HA. (2008). Schizophrenia, 'Just the Facts'. What we know in 2008. 2. Epidemiology and etiology. Schizophr Res 102:1-18.
52. Wirshing DA. (2004). Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psych 65:13-26.
53. Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM. (2006). Insulin receptor defciets in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 84:1-14.